Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

B Statistically Significant Reduction in Srebf1 (Fat Production) and Increased PparĪ± (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April…
posteditor
posteditor
Articles: 16137

Other News